Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Astrocytoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
647 results:

  • 1. DKK3 Expression in Glioblastoma: Correlations with Biomolecular Markers.
    Caffo M; Casili G; Caruso G; Barresi V; Campolo M; Paterniti I; Minutoli L; Ius T; Esposito E
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612910
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Glioblastoma Therapy: Past, Present and Future.
    Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine.
    Wang J; Xi YF; Zhao Q; Guo JH; Zhang Z; Zhang MB; Chang J; Wu YQ; Su W
    Mol Biol Rep; 2024 Mar; 51(1):385. PubMed ID: 38438773
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma Cells.
    Beltzig L; Christmann M; Dobreanu M; Kaina B
    Anticancer Res; 2024 Mar; 44(3):901-910. PubMed ID: 38423634
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
    Chen J; Laverty DJ; Talele S; Bale A; Carlson BL; Porath KA; Bakken KK; Burgenske DM; Decker PA; Vaubel RA; Eckel-Passow JE; Bhargava R; Lou Z; Hamerlik P; Harley B; Elmquist WF; Nagel ZD; Gupta SK; Sarkaria JN
    Sci Transl Med; 2024 Feb; 16(734):eadj5962. PubMed ID: 38354228
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Comparative assessment of direct and indirect cold atmospheric plasma effects, based on helium and argon, on human glioblastoma: an in vitro and in vivo study.
    Bakhtiyari-Ramezani M; Nohekhan M; Akbari ME; Abbasvandi F; Bayat M; Akbari A; Nasiri M
    Sci Rep; 2024 Feb; 14(1):3578. PubMed ID: 38347045
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Involvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate.
    Cooper E; Oyagawa CRM; Johnson R; Choi PJ; Foliaki JM; Correia J; Schweder P; Heppner P; Mee E; Turner C; Faull R; Denny WA; Dragunow M; Jose J; Park TI
    Cell Commun Signal; 2024 Jan; 22(1):30. PubMed ID: 38212807
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
    Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Circadian gene Per3 promotes astroblastoma progression through the p53/BCL2/BAX signalling pathway.
    Wang Q; Liu H; Wang Z; Chen Y; Zhou S; Hu X; Xu Y; Zhang X; Wang Y; Gao Y; Li S
    Gene; 2024 Feb; 895():147978. PubMed ID: 37951372
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comparative Analysis of IDH Wild-Type Multifocal and Unifocal Glioblastomas: Prognostic Factors and Survival Outcomes in Focus.
    Habiboglu R; Kayali I; Saricanbaz I; Tezcan Y
    Turk Neurosurg; 2023; 33(6):1126-1131. PubMed ID: 37846543
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma.
    Zhang W; Vaubel RA; Oh JH; Mladek AC; Talele S; Zhang W; Waller KL; Burgenske DM; Sarkaria JN; Elmquist WF
    Mol Cancer Ther; 2024 Jan; 23(1):47-55. PubMed ID: 37828724
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. ROCK inhibition reduces the sensitivity of mutant p53 glioblastoma to genotoxic stress through a Rac1-driven ROS production.
    Magalhaes YT; Forti FL
    Int J Biochem Cell Biol; 2023 Nov; 164():106474. PubMed ID: 37778694
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Network pharmacology -based study on the mechanism of traditional Chinese medicine in the treatment of glioblastoma multiforme.
    Liang C; Zhang B; Li R; Guo S; Fan X
    BMC Complement Med Ther; 2023 Sep; 23(1):342. PubMed ID: 37759283
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth.
    Della Monica R; Buonaiuto M; Cuomo M; Pagano C; Trio F; Costabile D; de Riso G; Cicala FS; Raia M; Franca RA; Del Basso De Caro M; Sorrentino D; Navarra G; Coppola L; Tripodi L; Pastore L; Hench J; Frank S; Schonauer C; Catapano G; Bifulco M; Chiariotti L; Visconti R
    Cell Death Dis; 2023 Sep; 14(9):638. PubMed ID: 37758718
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review.
    Nahar Metu CL; Sutihar SK; Sohel M; Zohora F; Hasan A; Miah MT; Rani Kar T; Hossain MA; Rahman MH
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1889. PubMed ID: 37675821
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
    Miranda J; Vázquez-Blomquist D; Bringas R; Fernandez-de-Cossio J; Palenzuela D; Novoa LI; Bello-Rivero I
    BMC Cancer; 2023 Aug; 23(1):806. PubMed ID: 37644431
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Raf/MEK/ERK Signaling Pathway Is Involved in the Inhibition of Glioma Cell Proliferation and Invasion in the Ketogenic Microenvironment.
    Fan WT; Liu XF; Liang RC
    Curr Med Sci; 2023 Aug; 43(4):759-767. PubMed ID: 37498407
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
    Cappelli L; Khan MM; Kayne A; Poiset S; Miller R; Ali A; Niazi M; Shi W; Alnahhas I
    Chin Clin Oncol; 2023 Jun; 12(3):23. PubMed ID: 37417289
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Immune micro-environment analysis and establishment of response prediction model for PD-1 blockade immunotherapy in glioblastoma based on transcriptome deconvolution.
    Wong D; Yin Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11689-11703. PubMed ID: 37407848
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. p53 status, and G2/M cell cycle arrest, are determining factors in cell-death induction mediated by ELF-EMF in glioblastoma.
    Mehdizadeh R; Madjid Ansari A; Forouzesh F; Shahriari F; Shariatpanahi SP; Salaritabar A; Javidi MA
    Sci Rep; 2023 Jul; 13(1):10845. PubMed ID: 37407632
    [TBL] [Abstract] [Full Text] [Related]  


    of 33.